“I’m Just Tired”: Listening for the Words Patients Actually Use
ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.
Investigational Oral Medication for OSA Meets Primary Endpoints in Phase 3 Clinical Trial
The anti-apneic neuromuscular modulator AD109 targets the root cause of OSA by increasing upper airway muscle tone during sleep, according to Apnimed.
FDA Grants Novavax COVID-19 Vaccine Full Approval for High-Risk Groups
Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.
Laxmi Gannu, MS, Explains a New Study of Clinician's Knowledge of Post Partum Depression
ACOG 2025: The Junonia study was designed to understand gaps in care for women with PPD using surveys of their clinicians and care coordinators.
Nanette Santoro, MD, Highlights Findings on Fezolinetant From Pooled Analysis of Phase 3 Skylight Development Program Trials
The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.
When We Talk About Perinatal Weight Issues, We Need to Focus on the Whole Person, Johanna Finkle, MD, Reminds Clinicians
ACOG 2025: Pregnant patients may not want to discuss weight gain initially, so focus on overall perinatal health, and use that information to guide more conversation.
Study Shows Sharp Rise in GI Cancers Among Young Adults: Daily Dose
Your daily dose of the clinical news you may have missed.
Why Postpartum Depression Is Still Off the Radar in Pregnancy Care
LeThenia Joy Baker, MD, explains why PPD is often overlooked compared to physical pregnancy conditions like gestational diabetes.
Postpartum Inpatient HPV Vaccination Significantly Boosts Uptake at Urban Hospital, Study Finds
An intervention that included educational materials for clinicians on a multidisciplinary prenatal and postpartum care team helped drive acceptance.
Prenatal Substance Use Counseling: Missed Opportunities for Intervention
Pregnant patients' perceptions do not match clinician certainty on abstinence counseling during pregnancy, and clinicians may not be asking patients about their partner's substance use.
Study Reveals Major Gaps in Thyroid Screening During Pregnancy
Researchers report an alarming number of missed opportunities to screen pregnant individuals for thyroid disease, including among women with a history of the condition.
Joy Baker, MD: Understanding Patient Language in PPD Screening
ACOG 2025: Dr Baker shares how language can help create a trusting space for patients to speak openly about postpartum depression.
Postpartum Depression and the Missed Hand-Off to Primary Care
ACOG 2025: Joy Baker, MD, called for stronger cross-specialty collaboration to address maternal mental health after birth.
ACOG 2025: Steven Fleischman, MD, Inaugurated as 76th President, Urges New Fellows to Lead with Purpose
Steven Fleischman, MD, was inaugurated as ACOG’s 76th president, urging new fellows to lead with purpose and recognize their value in women’s health care.
FDA Clears First Plasma-Based Assay to Aid Alzheimer Disease Diagnosis
The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.
Primary Care Falls Short in Managing Adolescent Heavy Menstrual Bleeding, Researchers Warn
Fewer than half of females who experienced heavy menstrual bleeding were given hormonal treatment, and far fewer were referred to gynecology, authors reported.
GLP1-RAs Superior to Metformin for CVD Risk Reduction in Women with PCOS, Large Study Finds
The findings support the potential cardiovascular advantages of the GLP-1RA class in women with PCOS, a population already at increased cardiometabolic risk.
Study Identifies 6 Components of a Pregnancy Exercise Program that Reduce Risk of Poor Perinatal Outcomes
While exercise is beneficial during pregnancy and ACOG recommends 150 mins/week, this is the first study to examine benefits of specific regimen elements on their own.
Fezolinetant Demonstrates Reduced Waist Circumference, Body Roundness and Stable Weight and BMI in 52-Week Pooled Analysis of Phase 3 SKYLIGHT Trials
Postmenopausal women taking fezolinetant experienced positive changes in body fat distribution, increases in which are known to increase risks of cardiometabolic disease.
Elinzanetant Demonstrates Clinically Meaningful Reductions in Menopausal Vasomotor Symptoms, Meta-analysis Shows
Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.
